PRMT5 and lung carcinoma: Our findings present solid proof of a strong association between PRMT5 and angiogenesis/EMT and imply that inhibiting PRMT5 activity could be a viable therapeutic strategy for combating lung cancer that exhibits abnormal angiogenesis.